セキ　マサフミ   SEK Masafumi   関　雅文    所属   埼玉医科大学  医学部 国際医療センター　感染症科・感染制御科    職種   教授
論文種別	学術雑誌(原著)
言語種別	英語
査読の有無	査読あり
表題	Clinical practice guidelines for therapeutic drug monitoring of arbekacin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.
掲載誌名	正式名：Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
巻・号・頁	20(1),1-5頁
著者・共著者	Kenji Okada,Toshimi Kimura,Hiroshige Mikamo,Kei Kasahara,Masafumi Seki,Shunji Takakura,Issei Tokimatsu,Norio Ohmagari,Yoshiko Takahashi,Kazuaki Matsumoto,Masahiro Igarashi,Masahiro Kobayashi,Yukihiro Hamada,Takahiro Mochizuki,Masao Kimura,Yoshifumi Nishi,Yusuke Tanigawara,Yoshio Takesue
発行年月	2014/01
概要	Arbekacin (ABK) was approved and widely used in Japan for treatment of patients infected with MRSA, and TDM was introduced in clinical practice. The Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring decided to develop a clinical practice guidelines for TDM of ABK for the following reasons. First, although the daily dose of 150-200 mg was approved in Japan, recent PK-PD studies revealed that higher serum concentration is required to achieve better clinical efficacy and several findings concerning the usefulness of higher dosage regimen have obtained recently. Second, although maximal concentrations that obtainedimmediately after the end of administration (Cmax) was generally adopted, the serum concentration at 1 h after initiation of administration [peak serum concentration (Cpeak)]proved to be more suitable as an efficacy indicator of aminoglycosides. Lastly, as ABK is approved only in Japan, no international practice guideline for TDM has not been available in ABK to date. This guideline evaluated the scientific data associated with serum ABK monitoring and provided recommendations based on the available evidence. Potential limitations of
DOI	10.1016/j.jiac.2013.08.008
PMID	24486168